Bansi Nagji, CEO of PANTHERx Rare, argued in a March 27, 2026 guest post on Drug Channels that rare disease pharmacy is “fundamentally different” from traditional specialty pharmacy rather than a miniature version of it. He pointed out that more than 10,000 rare diseases collectively affect over 30 million Americans, comparable in prevalence to diabetes, but involve far smaller and more complex patient populations. Nagji described several dimensions of distinction: the clinical risk of managing tiny cohorts, the intricate logistics and monitoring required for fragile therapies, the urgency of rapid access to prevent irreversible harm (as in infants with hypophosphatasia), and the deeply collaborative prescriber-pharmacy relationships that enable hyper-personalized care.
This argument marks a quiet but significant shift in how manufacturers, payers, and pharmacies negotiate roles in the rare disease marketplace. If rare pharmacy is different by design, not merely by scale, then the old specialty contracting playbook of volume discounts and adherence metrics simply doesn’t apply. For companies launching single-indication treatments into near-zero patient populations, reimbursement and distribution terms now depend on service precision, data quality, and the ability to prove patient-level outcomes, not on bulk throughput. Payers and PBMs are already testing carve-out designs for rare pharmacy networks, drawing from the bespoke risk-sharing frameworks taking root in cell and gene therapy channels. Nobody really knows yet which model sticks.
It looks increasingly likely that PANTHERx is positioning itself to reshape how value is defined in the rare ecosystem, shifting from transactional fulfillment to a concierge-style model priced for clinical vigilance and speed-to-therapy. Should that framing hold, expect investors and drugmakers to rethink limited-distribution agreements, recalibrate which pharmacies qualify, and rewrite payer incentives accordingly. The next logical step, pharmacy performance directly tied to outcomes-based reimbursement, feels less like speculation and more like an inevitability. And frankly, it’s overdue.
